Keywords
vital functions
theramin
sustamar
tenoxicam
How to Cite
Abstract
Nowadays, lower back pain (LBP) has reached the level of a pandemic in advanced countries. The pathology restricts patients' activity, adversely affects their daily activities, and is a reason for frequent visiting doctors of various specialties. This is due to debilitating course of disease and, not infrequently, to the lack of therapeutic improvement resulting in the reduction of the life quality. Therefore, search for new approaches to eliminate pain syndrome and to improve patients' vital functions is both relevant and appropriate. The objective of this study was to determine the efficiency of separate and combined use of theramin, a medical food; sustamar, a herbal remedy; tenoxicam, a non-steroid anti-inflammatory drug in the patients with chronic lower back pain of vertebral genesis. Altogether, 140 patients with LBP were evaluated. They all were divided into 7 groups: group 1 – healthy persons (controls); group 2 – LBP patients before treatment; group 3 – patients who received theramin; group 4 – those who were given tenoxicam; group 5 – patients who received sustamar; group 6 – theremin and tenoxicam therapy; group 7 – sustamar and tenoxicam. Intensity of pain syndrome in LBP patients was found to be very severe, as indicated by the Visual Analogue Scale indicator, which increased 8.8 times as compared to the control group. This in turn resulted in considerable deterioration of these patients' vital functions that was confirmed by Oswestry Disability Index and Roland-Morris scale indicator, which increased by 27.4 and 18.1 times, respectively. The use of theramin, tenoxicam, and sustamar is efficient for the elimination of pain syndrome in LBP patients, thus positively affecting their vital functions. Theramin and tenoxicam combination was found to be more effective in comparison with that of tenoxicam and sustamar (p<0.05) regarding ability to relieve pain syndrome in LBP patients. What concerns the effect on the vital functions of LBP patients, drug combinations were almost identical, however reliably superior to their separate use.
Keywords: pain intensity, vital functions, theramin, sustamar, tenoxicam.
References
Kuritzky L, Samraj GP. Nonsteroidal anti-inflammatory drugs in the treatment of low back pain. Journal of Pain Research. 2012;5:579-90. DOI: 10.2147/JPR.S6775. PMID: 23271922.
Jousimaa J. Pain in the lower back. Instruction 00435. Guidelines based on evidence-based medicine. Adapted for Ukraine by a group of experts from the Ministry of Health of Ukraine: Malmivaara A, Pohjolainen T, Hirvensalo E, Jousimaa J. DUODECIM Medical Publications, Ltd., 2017. Available at: https://guidelines.moz.gov.ua/documents/2918?id=ebm00435 [in Ukrainian].
Nijs J, Apeldoorn A, Hallegraeff H, Clark J, Smeets R, Malfliet A, et al. Low Back Pain: Guidelines for the Clinical Classification of Predominant Neuropathic, Nociceptive, or Central Sensitization Pain. Pain Physician. 2015;18(3):333-46. PMID: 26000680.
Kopchak OO. The problem of lower back pain taking into account evidence- based medicine data. Int. Neurol. J. 2020;16(3):41-9. DOI: 10.22141/2224-0713.16.3.2020.202769.
MacNab I. Negative disc exploration: an analysis of the cause of nerve root involvement in sixty-eight patients. J. Bone Joint Surg. 1971;53(5):891-903. PMID: 4326746.
Fairbank JC, Couper J, Davies JB, O'Brien JP. The Oswestry low back pain disability questionnaire. Physiotherapy. 1980;66(8):271-3. PMID: 6450426.
Roland MO, Morris RW. A study of the natural history of back pain. Part 1: Development of a reliable and sensitive measure of disability in low back pain. Spine. 1983;8:141-4. DOI: 10.1097/00007632-198303000-00004. PMID: 6222486.
Coull JT, Hwang HJ, Leyton M, Dagher A. Dopamine precursor depletion impairs timing in healthy volunteers by attenuating activity in putamen and supplementary motor area. J. Neurosci. 2012;32(47):16704-15. DOI: 10.1523/JNEUROSCI.1258-12.2012. PMID: 23175824.
McCall T, Weil ZM, Nacher J, Bloss EB, El Maarouf A, Rutishauser U, McEwen BS. Depletion of polysialic acid from neural cell adhesion molecule (PSA-NCAM) increases CA3 dendritic arborization and increases vulnerability to excitotoxicity. Exp. Neurol. 2013;241:5-12. DOI: 10.1016/j.expneurol.2012.11.028. PMID: 23219884.
Mette C, Zimmermann M, Grabemann M, Abdel-Hamid M, Uekermann J, Biskup CS, et al. The impact of acute tryptophan depletion on attentional performance in adult patients with ADHD. Acta Psychiatr. Scand. 2013;128(2):124-32. DOI: 10.1111/acps.12090. PMID: 23419004.
Ablin JN, Buskila D, Van Houdenhove B, Luyten P, Atzeni F, Sarzi-Puttini P. Is fibromyalgia a discrete entity? Autoimmun Rev. 2012;11(8):585-8. DOI: 10.1016/j.autrev.2011.10.018. PMID: 22036826.
Serra A, Ruff RL, Leigh RJ. Neuromuscular transmission failure in myasthenia gravis: decrement of safety factor and susceptibility of extraocular muscles. Ann. N.Y. Acad. Sci. 2012;1275(1):129-35. DOI: 10.1111/j.1749-6632.2012.06841.x. PMID: 23278588.
Shell WE, Pavlik S, Roth B, Silver M, Breitstein ML, May L, Silver D. Reduction in pain and inflammation associated with chronic low back pain with the use of the medical food Theramine. Am. J. Ther. 2016;23(6):e1353-62. DOI: 10.1097/MJT.0000000000000068. PMID: 25237981.
Nilsen OG. Clinical pharmacokinetics of tenoxicam. Clin. Pharmacokinet. 1994;26(1):16-43. DOI: 10.2165/00003088-199426010-00003. PMID: 8137596.
Tenoxicam: features of use in clinical practice. Ukrainian Journal of Rheumatology. Editorial article. 2020;1(79):60-4. DOI: 10.32471/rheumatology.2707-6970.79.14869.
Oltean H, Robbins C, van Tulder MW, Berman BM, Bombardier C, Gagnier JJ. Herbal medicine for low-back pain. Cochrane Database Syst. Rev. 2014;12:CD004504. DOI:10.1002/14651858.CD004504.pub4. PMID: 25536022.
Polyakova DS. Sustamar: long-lasting effect – respect from the joints! Ukrainian Medical Journal. 2019;4(1):47. Available at: http://surl.li/qedbs
Gyurkovska V, Alipieva K, Maciuk A, Dimitrova P, Ivanovska N, Haas C, et al. Anti-inflammatory activity of Devil’s claw in vitro systems and their active constituents. Food Chem. 2011;125(1):171-8.
Ouitas NA, Heard CM. A novel ex vivo skin model for the assessment of the potential transcutaneous anti-inflammatory effect of topically applied Harpagophytum procumbens extract. Int. J. Pharm. 2009;376(1-2):63-8. DOI: 10.1016/j.ijpharm.2009.04.017. PMID: 19383533.
Loew D, Mollerfeld J, Schrodter A, Puttkammer S, Kaszkin M. Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. Clin. Pharmacol. Ther. 2001;69(5):356-64. DOI: 10.1067/mcp.2001.115445. PMID: 11372004.
Fiebich BL, Heinrich M, Hiller KO, Kammerer N. Inhibition of TNF-alpha synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69. Phytomedicine. 2001;8(1):28-30. DOI: 10.1078/0944-7113-00002. PMID: 11292236.
Chrubasik S, Chrubasik C, Kunzel O, Black A. Patient-perceived benefit during one year of treatment with Doloteffin. Phytomedicine. 2007;14(6):371-6. DOI: 10.1016/j.phymed.2007.04.011. PMID: 17521896.
Warnock M, McBean D, Suter A, Tan J, Whittaker P. Effectiveness and safety of Devil’s Claw tablets in patients with general rheumatic disorders. Phytother. Res. 2007;21(12):1228-33. DOI: 10.1002/ptr.2288. PMID: 17886223.
Lienert A, Ruetten S, Kuhn M, Wartenberg-Demand A. A randomised, active-controlled, mono-centric study of the herbal drug, Devil’s Claw (Harpagophytum procumbens) (ALLYA® tablets), Voltaren® and Vioxx® indicates equal efficacy in the treatment of patients with unspecific lumbar pain. Meeting abstr. 54. Proceedings of the 54th Annual Conference of the North German Orthopedic Association (Germany, Hamburg, 16–18 June 2005). P. 616-8. Available at: https://www.egms.de/static/en/meetings/nov2005/05nov108.shtml
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.